Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity

Stephanie W Waldrop; Veronica R Johnson; Fatima Cody Stanford

doi:10.1038/s41591-023-02669-x

Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity

Nat Med. 2024 Jan;30(1):22-25. doi: 10.1038/s41591-023-02669-x.

Authors

Stephanie W Waldrop^#¹, Veronica R Johnson^#², Fatima Cody Stanford³

Affiliations

¹ University of Colorado School of Medicine-Anschutz Medical Campus, Department of Pediatrics, Section on Nutrition and Lifestyle Medicine, Nutrition Obesity Research Center at the University of Colorado (CUNORC), Aurora, CO, USA. stephanie.waldrop@cuanschutz.edu.
² Northwestern University Feinberg School of Medicine, Department of Medicine, Division of General Internal Medicine, Chicago, IL, USA.
³ Massachusetts General Hospital, Massachusetts General Hospital Weight Center, Department of Medicine-Division of Endocrinology-Neuroendocrine, Department of Pediatrics-Division of Endocrinology, Nutrition Obesity Research Center at Harvard (NORCH), Boston, MA, USA.

^# Contributed equally.

PMID: 38172631
PMCID: PMC10921848 (available on 2025-01-01)
DOI: 10.1038/s41591-023-02669-x

Abstract

GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities.

MeSH terms

Diabetes Mellitus, Type 2*
Glucagon-Like Peptide-1 Receptor / agonists
Glucagon-Like Peptide-1 Receptor Agonists*
Humans
Hypoglycemic Agents
Obesity / drug therapy
Obesity / epidemiology

Substances

Glucagon-Like Peptide-1 Receptor Agonists
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor

Abstract

MeSH terms

Substances

Grants and funding